Suppr超能文献

连续或复合淋巴瘤的发病模式:一项基于人群的癌症登记研究。

Incidence Patterns of Sequential or Composite Lymphoma: A Population-Based Cancer Registry Study.

机构信息

Department of Clinical Epidemiology, Graduate School of Biomedical Sciences, Nagasaki University.

Department of Pathology, Sasebo City General Hospital.

出版信息

Tohoku J Exp Med. 2021 Jun;254(2):123-127. doi: 10.1620/tjem.254.123.

Abstract

The development of multiple histologic types of lymphoma in a single patient has been sporadically reported as sequential or composite lymphoma. However, the incidence pattern of such patients has been rarely evaluated in a large population-based setting. We investigated the incidence of sequential or composite lymphoma based on 11,174 lymphoma records from a population-based cancer registry between 1985-2012 in Nagasaki Prefecture, Japan. We identified 99 lymphoma records were of 49 independent patients other than relapse. The prevalence of the sequential or composite lymphomas in a single patient was 0.44% (95% confidence interval [95% CI], 0.32-0.56%) without sex difference. Among the 49 patients, five (10.2%) were composite/discordant lymphoma. The most frequent "composite lymphoma" was a combination of diffuse large B-cell lymphomas (DLBCL) and adult T-cell leukemia (n = 3). A case of "discordant lymphoma" was a combination of follicular lymphoma on spleen and Waldenström macroglobulinemia on bone marrow. The rest of the patients (n = 44, 89.8% of all composite lymphoma) were "sequential lymphoma" with various combination of lymphoma subtypes on different dates. The major combination of the sequential lymphoma was DLBCL after marginal zone lymphomas (n = 4). In the era of improved survival of lymphoma patients, hematologists should be aware of the development of additional lymphomas.

摘要

在单个患者中同时发生多种组织学类型的淋巴瘤,这种情况曾被零星报道为序贯性或复合性淋巴瘤。然而,在大规模基于人群的研究中,这种患者的发病模式很少得到评估。我们根据日本长崎县 1985-2012 年间人群癌症登记处的 11174 例淋巴瘤记录,研究了序贯性或复合性淋巴瘤的发病率。我们确定了 99 例淋巴瘤记录来自 49 例非复发的独立患者。在单个患者中,序贯性或复合性淋巴瘤的患病率为 0.44%(95%置信区间[95%CI],0.32-0.56%),无性别差异。在这 49 例患者中,有 5 例(10.2%)为复合/不一致性淋巴瘤。最常见的“复合性淋巴瘤”是弥漫性大 B 细胞淋巴瘤(DLBCL)和成人 T 细胞白血病(n = 3)的组合。1 例“不一致性淋巴瘤”是脾滤泡性淋巴瘤和骨髓 Waldenström 巨球蛋白血症的组合。其余患者(n = 44,所有复合性淋巴瘤的 89.8%)为“序贯性淋巴瘤”,在不同日期出现不同淋巴瘤亚型的各种组合。序贯性淋巴瘤的主要组合是边缘区淋巴瘤后 DLBCL(n = 4)。在淋巴瘤患者生存得到改善的时代,血液科医生应该意识到其他淋巴瘤的发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验